Table 1.
Characteristics of patients and controls.
| Parameters | Newly diagnosed MM | Responders | At relapse | Progressive disease | Controls |
|---|---|---|---|---|---|
| Number of subjects | 50 | 47 | 39 | 16 | 41 |
| Gender (M/F) | 27/23 | 23/24 | 20/19 | 10/6 | 8/5 |
| Age | 62 (30–85) | 64 (42–86) | 69 (42–86) | 68 (55–83) | 67 (49–80) |
| Monoclonal component | |||||
| IgGk-IgGλ-IgAk-IgAλ | 22-10-12-6 | 18-14-11-4 | 21-15-3-0 | 8-5-1-2 | |
| ISS-stage | ISS-1: 23 | ISS-1: 19 | ISS-1: 16 | ISS-1: 8 | |
| ISS-2: 7 | ISS-2: 12 | ISS-2: 7 | ISS-2: 3 | ||
| ISS-3: 20 | ISS-3: 16 | ISS-3: 16 | ISS-3: 5 | ||
| Hb g/dL. median (range) | 11.2 ± 0.4 (7.6–15) | 12 ± 0.22 (8.8–15.4) | 10.8 ± 0.37 (7.8–15.7) | 11.5 ± 0.34 (8.3–16.1) | |
| LDH U/L. median (range) | 188 ± 32.64 (129–800) | 187 ± 9.49 (124–475) | 181 ± 29.70 (125–807) | 156 ±53.97 (122–1,503) | |
| Serum Creatinine mg/dL median (range) | 0.92 ± 0.37 (0.60–10) | 0.84 ± 0.16 (0.45–7.07) | 0.93 ± 0.33 (0.47–9.42) | 0.96 ± 0.08 (0.53–2.36) | |
| Serum Calcium mg/dL. median (range) | 9.2 ± 0.09 (8.5–12) | 8.9 ± 0.05 (8.6–9.6) | 9.08 ± 0.09 (8.20–10) | 9 ± 0.27 (9.1–11.1) | |
| Bone Disease | 37 | 38 | 34 | 12 |